SCHEMBL204451

SCHEMBL204451

CC1(C)OB(c2ccc3c(c2)CCc2cc(B4OC(C)(C)C(C)(C)O4)ccc2-3)OC1(C)C

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LPL P06858 13/20 0.46
LIPG Q9Y5X9 13/20 0.46
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA9 Q16790 2/20 0.39
CA12 O43570 1/20 0.39
CA3 P07451 1/20 0.39
CA4 P22748 1/20 0.39
CA6 P23280 1/20 0.39
CA5A P35218 1/20 0.39
CA7 P43166 1/20 0.39
CA14 Q9ULX7 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
ROCK1 Q13464 1/20 0.39
F11 P03951 1/20 0.38
P2RX7 Q99572 1/20 0.38
MAPK1 P28482 1/20 0.36
BACE1 P56817 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24411917 0.91 LPL (0.39) LPLLIPGROCK1F11
SCHEMBL13070935 0.91 LPL (0.39) LPLLIPGCA1CA2CA9
SCHEMBL202622 0.89 LIPG (0.46) LPLLIPGCA1CA2CA9
SCHEMBL30860136 0.89 LIPG (0.46) LPLLIPGCA1CA2CA9
SCHEMBL483144 0.89 CASP1 (0.45) LPLLIPGCA1CA2CA9
SCHEMBL31222883 0.89 CASP1 (0.45) LPLLIPGCA1CA2CA9
SCHEMBL15429671 0.88 LIPG (0.49) LPLLIPGCA1CA2CA9
SCHEMBL16639375 0.87 LPL (0.47) LPLLIPGCA1CA2CA9
SCHEMBL29502333 0.87 LPL (0.47) LPLLIPGCA1CA2CA9
SCHEMBL23767233 0.85 LPL (0.44) LPLLIPGROCK1F11P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024136111-A1 FLUORENE-BASED POLYMER, ANION EXCHANGE MEMBRANE, WATER-ELECTROLYSIS DEVICE, AND CARBON DIOXIDE CONVERSION DEVICE 에스케이이노베이션 주식회사 2024-06-27 WO disclosed
EP-3699176-A2 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2020-08-26 EP disclosed
US-20200123132-A1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC 2020-04-23 US disclosed
EP-3626716-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2020-03-25 EP disclosed
US-10559756-B2 Materials for electronic devices MERCK PATENT GMBH (DE) 2020-02-11 US disclosed
US-10344019-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2019-07-09 US disclosed
US-9981955-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2018-05-29 US disclosed
US-9981955-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2018-05-29 US disclosed
EP-3309157-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2018-04-18 EP disclosed
EP-3309157-A1 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2018-04-18 EP disclosed
US-8088368-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-8088368-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed
US-20100310512-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2010-12-09 US disclosed
WO-2010132601-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-11-18 WO disclosed
US-20090036623-A1 PROCESS FOR PRODUCING CONJUGATED POLYMER HITACHI CHEMICAL CO., LTD. (JP) 2009-02-05 US disclosed
US-20090036623-A1 PROCESS FOR PRODUCING CONJUGATED POLYMER HITACHI CHEMICAL CO., LTD. (JP) 2009-02-05 US disclosed
US-20070003783-A1 Quinoline copolymer and organic electroluminescent device employing same HITACHI CHEMICAL CO LTD (JP) 2007-01-04 US disclosed
US-20070003783-A1 Quinoline copolymer and organic electroluminescent device employing same HITACHI CHEMICAL CO LTD (JP) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344019-B2 Antiviral compounds MAVS, EIF2AK2, ZC3HAV1 LPL 2383/4885LIPG 1280/4885CA1 4745/4885
US-10559756-B2 Materials for electronic devices TEC, EFNA1, BMI1 LPL 4510/4885LIPG 3626/4885CA1 3105/4885
US-20200123132-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 LPL 2383/4885LIPG 1280/4885CA1 4745/4885
US-20100310512-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 LPL 2383/4885LIPG 1280/4885CA1 4745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.